Dapagliflozin’s CV Effects Consistent Across Baseline Kidney Function
Reductions in cardiovascular risk associated with dapagliflozin treatment in patients with type 2 diabetes are most pronounced in those who have both reduced kidney function and albuminuria, a recent analysis shows.